The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Central nervous system (CNS) development is a finely tuned process that relies on multiple factors and intricate pathways to ensure proper neuronal differentiation, maturation, and connectivity. Disruption of this process can cause significant impairments in CNS functioning and lead to debilitating disorders that impact motor and language skills, behavior, and cognitive functioning. Recent studies focused on understanding the underlying cellular mechanisms of neurodevelopmental disorders have identified a crucial role for insulin-like growth factor-1 (IGF-1) in normal CNS development. Work in model systems has demonstrated rescue of pathophysiological and behavioral abnormalities when IGF-1 is administered, and several clinical studies have shown promise of efficacy in disorders of the CNS, including autism spectrum disorder (ASD). In this review, we explore the molecular pathways and downstream effects of IGF-1 and summarize the results of completed and ongoing pre-clinical and clinical trials using IGF-1 as a pharmacologic intervention in various CNS disorders. This aim of this review is to provide evidence for the potential of IGF-1 as a treatment for neurodevelopmental disorders and ASD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Baio, J., Wiggins, L., Christensen, D. L., Maenner, M. J., Daniels, J., Warren, Z., Kurzius-Spencer, M., Zahorodny, W., Robinson, C., Rosenberg, et al. (2018) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss6706a1 · Cited by 6,078
Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2
Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francke, U., & Zoghbi, H. Y. (1999) · Nature Genetics · doi:10.1038/13810 · Cited by 4,990 · cited 1×
“The IGF-1 in Neurodevelopmental Disorders Costales & Kolevzon 31 cause of Rett syndrome has been linked to a mutation in Xq28, the gene encoding MeCP2, which is a global transcriptional modulator (Amir et al., 1999).”
BackgroundMaenner, M. J., Shaw, K. A., Baio, J., EdS1, Washington, A., Patrick, M., DiRienzo, M., Christensen, D. L., Wiggins, L. D., Pettygrove, S., et al. (2020) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss6904a1 · Cited by 3,780
Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
Role of insulin-like growth factors in embryonic and postnatal growth
Baker, J., Liu, J.-P., Robertson, E. J., & Efstratiadis, A. (1993) · Cell · doi:10.1016/s0092-8674(05)80085-6 · Cited by 2,463
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072 · cited 2×
“In addition, many different genetic causes of ID and ASD, like Fragile X syndrome (FXS), converge on several underlying pathways, including the SHANK3 pathway (Darnell et al., 2011; Sakai et al., 2011).”
BackgroundStitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O., Gonzalez, M., Yancopoulos, G. D., & Glass, D. J. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00211-4 · Cited by 1,964
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
Alzheimer's Disease and the Amyloid-β Peptide
Murphy, M. P., & LeVine, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1221 · Cited by 1,750 · cited 1×
“The cause of AD has been related to aggregation of beta-amyloid in the brain, extracellular Aβ protein aggregation, and inflammation leading to neuronal apoptosis (C. Ballard et al., 2011; Murphy & LeVine, 2010; Roberts et al., 2008).”
BackgroundDurand, C. M., Betancur, C., Boeckers, T. M., Bockmann, J., Chaste, P., Fauchereau, F., Nygren, G., Rastam, M., Gillberg, I. C., Anckarsäter, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1933 · Cited by 1,602 · cited 1×
“Loss of SHANK3 is responsible for at least 0.5% of ASD cases (Durand et al., 2007) and up to 2% of ASD with moderate to profound intellectual disability (ID) (Leblond et al., 2014) .”
BackgroundInfluentialExperimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
Altered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349
Abnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits
Comery, T. A., Harris, J. B., Willems, P. J., Oostra, B. A., Irwin, S. A., Weiler, I. J., & Greenough, W. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5401 · Cited by 1,046 · cited 1×
“…level, both human Fragile X neurons and Fmr1 knockout mice have an abundance of dysmorphic dendritic spines and immature synapse formation, (Comery et al., 1997; Galvez & Greenough, 2005; Irwin, Galvez, & Greenough, 2000) thought to be caused by alterations in the PI3K/mTOR and MAPK/ERK…”
BackgroundThorne, R. G., Pronk, G. J., Padmanabhan, V., & Frey, W. H. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.029 · Cited by 958
Betancur, C. (2011) · Brain Research · doi:10.1016/j.brainres.2010.11.078 · Cited by 954
The many faces of insulin-like peptide signalling in the brain
Fernandez, A. M., & Torres-Alemán, I. (2012) · Nature reviews. Neuroscience · doi:10.1038/nrn3209 · Cited by 872
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764 · cited 1×
“After the discovery that lower IGF-1 levels are associated with AD, trials were conducted to explore the therapeutic properties of IGF-1 in mice with increased cerebral beta-amyloid plaques (Moloney et al., 2010; Mustafa et al., 1999; Watanabe et al., 2005).”
BackgroundDani, V. S., Chang, Q., Maffei, A., Turrigiano, G. G., Jaenisch, R., & Nelson, S. B. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506071102 · Cited by 639 · cited 1×
“This alteration in the cortical circuitry resulted in decreased neuronal activity and may also reduce long-term potentiation, which has been observed in MeCP2 mutant mice (Collins et al., 2004; Dani et al., 2005).”
BackgroundBeck, K. D., Powell-Braxtont, L., Widmer, H.-R., Valverde, J., & Hefti, F. (1995) · Neuron · doi:10.1016/0896-6273(95)90216-3 · Cited by 636
Leblond, C. S., Nava, C., Polge, A., Gauthier, J., Huguet, G., Lumbroso, S., Giuliano, F., Stordeur, C., Depienne, C., Mouzat, K., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004580 · Cited by 630 · cited 1×
“Loss of SHANK3 is responsible for at least 0.5% of ASD cases (Durand et al., 2007) and up to 2% of ASD with moderate to profound intellectual disability (ID) (Leblond et al., 2014) .”
BackgroundInfluentialMild overexpression of MeCP2 causes a progressive neurological disorder in mice
Collins, A. L., Levenson, J. M., Vilaythong, A. P., Richman, R., Armstrong, D. L., Noebels, J. L., David Sweatt, J., & Zoghbi, H. Y. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh282 · Cited by 626
Dendritic Spine Structural Anomalies in Fragile-X Mental Retardation Syndrome
Irwin, S. A. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.10.1038 · Cited by 626
Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice
Tropea, D., Giacometti, E., Wilson, N. R., Beard, C., McCurry, C., Fu, D. D., Flannery, R., Jaenisch, R., & Sur, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812394106 · Cited by 593 · cited 2×
“Tropea et al. (2009) studied in vivo (1-3)IGF-1 treatment in Rett syndrome by using MeCP2 mutant mice.”
BackgroundRegulation of Dendritic Morphogenesis by Ras–PI3K–Akt–mTOR and Ras–MAPK Signaling Pathways
Kumar, V., Zhang, M.-X., Swank, M. W., Kunz, J., & Wu, G.-Y. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2284-05.2005 · Cited by 588
Bozdagi, O., Sakurai, T., Papapetrou, D., Wang, X., Dickstein, D. L., Takahashi, N., Kajiwara, Y., Yang, M., Katz, A. M., Scattoni, M. L., et al. (2010) · Molecular Autism · doi:10.1186/2040-2392-1-15 · Cited by 584 · cited 3×
“Electrophysiological studies of hippocampal neurons in Fmr1 knockout mice not only confirmed aberrant activation of PI3K/mTOR and MAPK/ERK pathways (Deacon et al., 2015), but also revealed reduced response to excitatory synaptic currents and enhanced glutamate receptor dependent LTD, suggesting the importance of FMRP,…”
BackgroundThe Shank family of scaffold proteins
Sheng, M., & Kim, E. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.11.1851 · Cited by 578
Synapsins as Regulators of Neurotransmitter Release
Hilfiker, S., Pieribone, V. A., Czernik, A. J., Kao, H.-T., Augustine, G. J., & Greengard, P. (1999) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1999.0378 · Cited by 537
Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP
Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521
SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients
Shcheglovitov, A., Shcheglovitova, O., Yazawa, M., Portmann, T., Shu, R., Sebastiano, V., Krawisz, A., Froehlich, W., Bernstein, J. A., Hallmayer, J. F., et al. (2013) · Nature · doi:10.1038/nature12618 · Cited by 470 · cited 4×
“IGF-1 has reversed deficits in mouse (Bozdagi et al., 2013) and human neuronal (Shcheglovitov et al., 2013) models of PMS and is currently being administered as a therapeutic agent in a study in children with PMS, the preliminary results of which are promising (Kolevzon et al., 2014).”
BackgroundInfluentialClinical manifestations and stages of rett syndrome
Hagberg, B. (2002) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.10020 · Cited by 416
Autism: Many Genes, Common Pathways?
Geschwind, D. H. (2008) · Cell · doi:10.1016/j.cell.2008.10.016 · Cited by 328 · cited 1×
“…growth factors (including IGF-1), ERK targets nuclear transcription factors, which are important in inducing expression of genes that promote cell survival, division and motility (Clerk, Aggeli, Stathopoulou, & Sugden, 2006; Dhillon, Hagan, Rath, & Kolch, 2007; Geschwind, 2008; Pende et al., 2004).”
BackgroundErythropoietin as an antiapoptotic, tissue-protective cytokine
Ghezzi, P., & Brines, M. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401450 · Cited by 327 · cited 1×
“One such cytokine is erythropoietin (EPO), which has overlapping functions with IGF-1 pathways and function in vivo to protect neurons from ischemic damage (Buemi et al., 2005; Fischer, Wiesnet, Marti, Renz, & Schaper, 2004; Ghezzi & Brines, 2004).”
BackgroundShank Expression Is Sufficient to Induce Functional Dendritic Spine Synapses in Aspiny Neurons
Roussignol, G., Ango, F., Romorini, S., Tu, J. C., Sala, C., Worley, P. F., Bockaert, J., & Fagni, L. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4354-04.2005 · Cited by 293
A role for TGF-beta in oligodendrocyte differentiation.
McKinnon, R. D., Piras, G., Ida, J. A., & Dubois-Dalcq, M. (1993) · The Journal of cell biology · doi:10.1083/jcb.121.6.1397 · Cited by 248
Arsenijevic, Y., & Weiss, S. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-06-02118.1998 · Cited by 243 · cited 2×
“…Disorders Costales & Kolevzon 12 Clinical Considerations After crossing the BBB, IGF-1 has been shown to promote neuronal growth and development (Arsenijevic & Weiss, 1998; Hodge et al., 2004; Jorntell & Hansel, 2006; Torres-Aleman et al., 1990), leading it to be the focus of many clinical and…”
BackgroundFunctional recovery with recombinant human IGF1 treatment in a mouse model of Rett syndrome
Castro, J., Garcia, R. I., Kwok, S., Banerjee, A., Petravicz, J., Woodson, J., Mellios, N., Tropea, D., & Sur, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311685111 · Cited by 242 · cited 1×
“…al. (2004) used rhIGF-1 to treat MeCP2 mutant mice with intraperitoneal injections of either 0.25mg/kg or 2.5mg/kg daily for 14 days and demonstrated an overall reversal of neuronal circuitry signaling, improved social behaviors, and increased plasticity in developing neurons (Castro et al., 2014).”
MethodGalvez, R., & Greenough, W. T. (2005) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30709 · Cited by 231 · cited 1×
“…Fragile X neurons and Fmr1 knockout mice have an abundance of dysmorphic dendritic spines and immature synapse formation, (Comery et al., 1997; Galvez & Greenough, 2005; Irwin, Galvez, & Greenough, 2000) thought to be caused by alterations in the PI3K/mTOR and MAPK/ERK signaling pathways…”
BackgroundProtein interactome reveals converging molecular pathways among autism disorders
Sakai, Y., Shaw, C. A., Dawson, B. C., Dugas, D. V., Al-Mohtaseb, Z., Hill, D. E., & Zoghbi, H. Y. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002166 · Cited by 226 · cited 10×
“Fragile X Syndrome FXS is an X-linked disease caused by a mutation in the Fmr1 gene, which codes for the fragile X mental retardation protein (FMRP), another ASD-associated protein.”
BackgroundInfluentialFreude, S., Hettich, M. M., Schumann, C., Stöhr, O., Koch, L., Köhler, C., Udelhoven, M., Leeser, U., Müller, M., Kubota, N., et al. (2009) · The FASEB Journal · doi:10.1096/fj.09-132043 · Cited by 218 · cited 1×
“In addition, Freude et al (2009) showed that resistance to IGF-1 IGF-1 in Neurodevelopmental Disorders Costales & Kolevzon 25 delayed amyloid accumulation and prevented premature death in mouse models of AD (Freude et al., 2009).”
BackgroundBoeckers, T. M., Winter, C., Smalla, K.-H., Kreutz, M. R., Bockmann, J., Seidenbecher, C., Garner, C. C., & Gundelfinger, E. D. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1489 · Cited by 200 · cited 1×
“In addition to its role as a scaffolding protein, it also facilitates cross-talk between various receptor signaling pathways (Boeckers et al., 1999; Sheng & Kim, 2000).”
BackgroundAltered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome
Hoeffer, C. A., Sanchez, E., Hagerman, R. J., Mu, Y., Nguyen, D. V., Wong, H., Whelan, A. M., Zukin, R. S., Klann, E., & Tassone, F. (2012) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2012.00768.x · Cited by 198
Interactions of IGF-1 with the Blood-Brain Barrier in vivo and in situ
Pan, W., & Kastin, A. J. (2000) · Neuroendocrinology · doi:10.1159/000054584 · Cited by 185
Bozdagi, O., Tavassoli, T., & Buxbaum, J. D. (2013) · Molecular Autism · doi:10.1186/2040-2392-4-9 · Cited by 176
Pilpel, Y., Kolleker, A., Berberich, S., Ginger, M., Frick, A., Mientjes, E., Oostra, B. A., & Seeburg, P. H. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2008.160929 · Cited by 102
NNZ-2566, a novel analog of (1–3) IGF-1, as a potential therapeutic agent for fragile X syndrome
Deacon, R. M. J., Glass, L., Snape, M., Hurley, M. J., Altimiras, F. J., Biekofsky, R. R., & Cogram, P. (2015) · NeuroMolecular Medicine · doi:10.1007/s12017-015-8341-2 · Cited by 78 · cited 4×
“Electrophysiological studies of hippocampal neurons in Fmr1 knockout mice not only confirmed aberrant activation of PI3K/mTOR and MAPK/ERK pathways (Deacon et al., 2015), but also revealed reduced response to excitatory synaptic currents and enhanced glutamate receptor dependent LTD, suggesting the…”
BackgroundMethodInfluentialCorvin, A. P., Molinos, I., Little, G., Donohoe, G., Gill, M., Morris, D. W., & Tropea, D. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.05.029 · Cited by 57 · cited 3×
“The downstream effects of IGF-1 through the MAPK/ERK and PI3K/mTOR pathways were further explored in subsequent studies and it was discovered that IGF-1 does not produce all of its effect as an intact molecule (Corvin et al., 2012; Sara et al., 1993) .”
Background
Cited by
Dyer, A. H., Vahdatpour, C., Sanfeliu, A., & Tropea, D. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.03.056 · Cited by 377
Role of growth factors and cytokines in diabetic foot ulcer healing: A detailed review
Zubair, M., & Ahmad, J. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09492-1 · Cited by 329
Caldwell, A. L. M., Sancho, L., Deng, J., Bosworth, A., Miglietta, A., Diedrich, J. K., Shokhirev, M. N., & Allen, N. J. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01150-1 · Cited by 86
IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome
Araya, P., Kinning, K. T., Coughlan, C., Smith, K. P., Granrath, R. E., Enriquez-Estrada, B. A., Worek, K., Sullivan, K. D., Rachubinski, A. L., Wolter-Warmerdam, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111883 · Cited by 50
Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease
Reich, N., & Hölscher, C. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.614828 · Cited by 48
Metadata
- Authors
- Costales, J., & Kolevzon, A.
- Venue
- Neuroscience & Biobehavioral Reviews
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 63
- Pages
- 207-222
- ISSN
- 0149-7634 (ISSN-L)
- OpenAlex
- W2263547832
- Cited by
- 93
- References
- 50
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.